Nice research Auk as always.
Here's another piece to the puzzle. Its the Aussie TGA PAR (public assessment report) for Thromboreductin also proposed as an extended release drug. The application was made by Orphan Australia Pty Ltd as an alternative to Shire's Agrylin for ET. It was rejected by the TGA on manufacturing control grounds among others.
https://www.tga.gov.au/sites/default/files/auspar-anagrelide-hydrochloride-120507.pdf
The PDE-3 implications for the Anagrelide metabolite are also mentioned below.
By the way once the Artimist issue is sorted we will also get an rejection/approval paper a bit like this one above.
Anagrelide, page-199
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ALA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
0.010(5.41%) |
Mkt cap ! $205.1M | |||
| Open | High | Low | Value | Volume |
| 18.5¢ | 20.0¢ | 18.5¢ | $867.7K | 4.443M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 650036 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 181193 | 6 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| ALA (ASX) Chart |